Dynamk Capital, an Englewood Cliffs, NJ-based Life Sciences venture capital firm, held the first close of its new fund.
The new vehicle, on track for a final close in 2018, provides early stage capital to innovative companies providing tools, technologies and services within the Life Sciences sector. The portfolio companies will provide technologies and services that enable biopharmaceutical companies around the world to develop therapeutics faster and produce them more economically. By focusing on enabling tools utilized across the industry, Dynamk’s model leverages the growth of the several hundred billion-dollar biopharmaceutical industry, while mitigating risks inherent to therapeutics.
The fund expects to invest in 8-10 companies over the next several years.
Founded in 2016 and led by Daniella Kranjac, Managing Partner, Dynamk Capital is a venture capital firm investing in early stage life sciences companies.
Its investment strategy is centered on identifying companies developing technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics.